MedAssets remains a Top Pick, says RW Baird Baird continues to view MedAssets as a Top Pick ahead of Q4 results. The firm expects an inline quarter and guidance but sees reaccelerating results in the second half of 2014 and beyond. Shares are Outperform rated with a $28 price target.
Healthways, MedAssets partner in new five-year agreement Healthways (HWAY) has partnered with MedAssets (MDAS) to expand patient access to the Dr. Dean Ornish Program for Reversing Heart Disease. Under the five-year agreement, Healthways has contracted with MedAssets as its sales partner to accelerate deployment of the Ornish Reversal Program to hospitals, health systems and physician organizations. The Ornish Reversal Program is the most scientifically proven platform in lifestyle medicine for treating and reversing heart disease and other chronic conditions.